MA43762A - Vaccin contre le rsv - Google Patents
Vaccin contre le rsvInfo
- Publication number
- MA43762A MA43762A MA043762A MA43762A MA43762A MA 43762 A MA43762 A MA 43762A MA 043762 A MA043762 A MA 043762A MA 43762 A MA43762 A MA 43762A MA 43762 A MA43762 A MA 43762A
- Authority
- MA
- Morocco
- Prior art keywords
- vaccine against
- against rsv
- rsv
- vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18571—Demonstrated in vivo effect
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16163807 | 2016-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43762A true MA43762A (fr) | 2021-04-21 |
Family
ID=55661317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043762A MA43762A (fr) | 2016-04-05 | 2017-04-04 | Vaccin contre le rsv |
Country Status (18)
Country | Link |
---|---|
US (3) | US10729757B2 (fr) |
EP (1) | EP3439694A1 (fr) |
JP (2) | JP7233928B2 (fr) |
KR (3) | KR102401247B1 (fr) |
CN (1) | CN109069612A (fr) |
AU (1) | AU2017248018A1 (fr) |
BR (1) | BR112018070323A2 (fr) |
CA (1) | CA3018139A1 (fr) |
CL (1) | CL2018002825A1 (fr) |
EA (1) | EA201892250A1 (fr) |
IL (1) | IL262109B2 (fr) |
MA (1) | MA43762A (fr) |
MX (1) | MX2018012095A (fr) |
MY (1) | MY193584A (fr) |
PE (1) | PE20190433A1 (fr) |
PH (1) | PH12018501912A1 (fr) |
SG (1) | SG11201807912SA (fr) |
WO (1) | WO2017174564A1 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2988780T (pt) | 2013-04-25 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Polipeptídeos f de pré-fusão do rsv solúveis estabilizados |
ES2839880T3 (es) * | 2015-07-07 | 2021-07-06 | Janssen Vaccines & Prevention Bv | Vacuna contra el VRS |
CA2991540A1 (fr) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Polypeptides du virus respiratoire syncytial pre-fusion solubles stabilises |
PL3718565T3 (pl) | 2015-10-22 | 2022-09-19 | Modernatx, Inc. | Szczepionki przeciwko wirusom układu oddechowego |
EA039095B1 (ru) | 2016-04-05 | 2021-12-03 | Янссен Вэксинс Энд Превеншн Б.В. | Стабилизированные растворимые f-белки rsv до слияния |
SG11201807912SA (en) * | 2016-04-05 | 2018-10-30 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
KR102421049B1 (ko) | 2016-05-30 | 2022-07-15 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 융합-전 rsv f 단백질 |
MA47787A (fr) | 2017-03-15 | 2020-01-22 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
US11229692B2 (en) * | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
SG11202001458SA (en) * | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
US20220273787A1 (en) * | 2019-05-15 | 2022-09-01 | Janssen Vaccines & Prevention B.V. | Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine |
KR20220008816A (ko) * | 2019-05-15 | 2022-01-21 | 얀센 백신스 앤드 프리벤션 비.브이. | 아데노바이러스 기반 백신을 사용한 호흡기 세포융합 바이러스 감염의 예방적 치료 |
US20230233661A1 (en) | 2020-06-29 | 2023-07-27 | Janssen Vaccines & Prevention B.V. | Vaccine combination against repiratory syncytial virus infection |
CN112220921B (zh) * | 2020-08-25 | 2022-08-16 | 北京交通大学 | 一种针对呼吸道合胞病毒感染的组合疫苗 |
WO2022175479A1 (fr) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Associations de vaccins contre les infections par les souches a et b du virus respiratoire syncytial |
CN114277039A (zh) * | 2021-10-25 | 2022-04-05 | 浙江君怡生物科技有限公司 | 呼吸道合胞病毒mRNA疫苗及其制备方法和应用 |
WO2023198815A1 (fr) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Administration séquentielle d'adénovirus |
WO2024041773A1 (fr) * | 2022-08-22 | 2024-02-29 | Glaxosmithkline Biologicals Sa | Protéines rsv-f |
WO2024069420A2 (fr) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Compositions immunogènes comprenant un trimère de protéine f rsv |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
ATE336587T1 (de) | 1994-06-10 | 2006-09-15 | Genvec Inc | Adenoviren-vektor systeme und zelllinien |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
US5994128A (en) | 1995-06-15 | 1999-11-30 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
CA2177085C (fr) | 1996-04-26 | 2007-08-14 | National Research Council Of Canada | Lignees de cellules complements e1 de l'adenovirus |
BR9710030A (pt) | 1996-07-01 | 1999-08-10 | Rhone Poulenc Rorer Sa | Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida] |
FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
WO1998010087A1 (fr) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Vecteurs d'adenovirus de chimpanze |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
KR100503701B1 (ko) | 1996-11-20 | 2005-07-26 | 인트로겐 테라페티스, 인코퍼레이티드 | 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
CA2283253A1 (fr) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Lignees cellulaires de complementation de la region e1 d'un adenovirus |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
JP4358434B2 (ja) | 1998-02-17 | 2009-11-04 | シェーリング コーポレイション | ウイルスを含む組成物、およびウイルス調製物を濃縮するための方法 |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
EP1133316B1 (fr) | 1998-11-16 | 2009-01-21 | Introgen Therapeutics, Inc. | Formulation d'adenovirus pour therapie genique |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
PT1818408E (pt) | 1999-05-17 | 2011-11-15 | Crucell Holland Bv | Adenovírus recombinante do serótipo ad11 |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US7468181B2 (en) | 2002-04-25 | 2008-12-23 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
US20020041884A1 (en) | 2000-03-07 | 2002-04-11 | Evans Robert K. | Adenovirus formulations |
CA2415688A1 (fr) | 2000-05-08 | 2001-11-15 | Anand Rao | Traitement enzymatique des proteines de lactoserum permettant d'obtenir des peptides anti-hypertension, produits obtenus et traitement de l'hypertension chez les mammiferes |
AUPR878401A0 (en) | 2001-11-09 | 2001-12-06 | Biota Holdings Ltd | Methods for identifying or screening anti-viral agents |
EP1453536A4 (fr) | 2001-12-12 | 2009-08-26 | Mayne Pharma Int Pty Ltd | Composition pour la conservation de virus |
IL162404A0 (en) | 2002-01-18 | 2005-11-20 | Schering Ag | Stabilized formulations of adenovirus |
US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
NZ534865A (en) | 2002-04-25 | 2008-07-31 | Crucell Holland Bv | Stable adenoviral vectors and methods for propagation thereof |
DK1506287T3 (da) | 2002-05-14 | 2007-08-20 | Merck & Co Inc | Fremgangsmåder til oprensning af adenovirus |
SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
CA2496918A1 (fr) | 2002-08-28 | 2004-03-11 | Introgen Therapeutics Inc. | Procedes chromatographiques de purification d'adenovirus |
SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
CA2880061C (fr) | 2004-01-23 | 2018-03-13 | Agostino Cirillo | Porteurs de vaccin adenoviral de chimpanze |
WO2005080556A2 (fr) | 2004-02-23 | 2005-09-01 | Crucell Holland B.V. | Procedes de purification de virus |
DK1869171T4 (en) | 2005-04-11 | 2016-01-18 | Crucell Holland Bv | Virus cleaning using ultrafiltration |
US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
WO2007110409A1 (fr) | 2006-03-27 | 2007-10-04 | Crucell Holland B.V. | Compositions comprenant un adénovirus recombiné et un adjuvant |
WO2008133663A2 (fr) * | 2006-11-30 | 2008-11-06 | Government Of The United States Of America, As Represented By The Secretary, | Compositions immunogènes à codons modifiés et procédés d'utilisation |
US7901388B2 (en) | 2007-07-13 | 2011-03-08 | Bacoustics, Llc | Method of treating wounds by creating a therapeutic solution with ultrasonic waves |
RS55162B1 (sr) | 2007-12-24 | 2017-01-31 | Id Biomedical Corp Quebec | Rekombinantni rsv antigeni |
CA2717142A1 (fr) | 2008-02-29 | 2009-09-03 | Tibotec Pharmaceuticals | Procede d'identification d'inhibiteurs viraux utilisant une proteine de fusion de classe i |
KR101504392B1 (ko) | 2008-11-03 | 2015-03-19 | 크루셀 홀란드 비.브이. | 아데노바이러스 벡터의 제조방법 |
MX345700B (es) * | 2008-12-09 | 2017-02-10 | Novavax Inc | Proteinas f del vrs modificadas y metodos de uso de las mismas. |
JP5882741B2 (ja) | 2009-02-02 | 2016-03-09 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サルアデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用 |
SG176807A1 (en) | 2009-06-24 | 2012-01-30 | Id Biomedical Corp Quebec | Vaccine |
PE20121541A1 (es) | 2009-06-24 | 2012-12-21 | Glaxosmithkline Biolog Sa | Antigenos de virus de sincicio respiratorio recombinantes |
EP4218800A1 (fr) | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Compositions de protéine f rsv et leurs procédés de fabrication |
JP5762408B2 (ja) | 2009-08-13 | 2015-08-12 | クルセル ホランド ベー ヴェー | ヒト呼吸器合胞体ウイルス(rsv)に対する抗体および使用方法 |
AU2010305765B2 (en) | 2009-10-15 | 2015-07-02 | Crucell Holland B.V. | Method for the purification of adenovirus particles |
JP5465331B2 (ja) | 2009-10-15 | 2014-04-09 | クルセル ホランド ベー ヴェー | 高細胞密度の培養物からのアデノウイルスの精製方法 |
WO2011050168A2 (fr) | 2009-10-21 | 2011-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Immunogènes du rsv, anticorps dirigés contre le rsv et compositions associées |
EP2536829B1 (fr) | 2010-02-15 | 2016-04-06 | Crucell Holland B.V. | Procédé de production de vecteurs adénoviraux Ad26 |
CN106188284B (zh) | 2010-07-09 | 2020-05-08 | 扬森疫苗与预防公司 | 抗人呼吸道合胞病毒(rsv)抗体以及使用方法 |
LT2707385T (lt) | 2011-05-13 | 2017-12-11 | Glaxosmithkline Biologicals Sa | Iš anksto sulieti rsv f antigenai |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
SI2825640T1 (sl) | 2012-03-12 | 2016-08-31 | Crucell Holland B.V. | Šarže rekombinantnega adenovirusa s spremenjenimi konci |
SG11201405803PA (en) | 2012-03-22 | 2014-11-27 | Crucell Holland Bv | Vaccine against rsv |
WO2014005643A1 (fr) | 2012-07-05 | 2014-01-09 | Okairos Ag | Nouveaux régimes de primo-vaccination-rappel impliquant des polypeptides immunogènes codés par des polynucléotides |
WO2014077096A1 (fr) * | 2012-11-15 | 2014-05-22 | 一般財団法人化学及血清療法研究所 | Procédé de prévention d'infections à l'aide d'une association d'un vaccin vecteur et d'un vaccin vivant |
US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
AU2014243756B2 (en) | 2013-03-13 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
EP2986638A1 (fr) | 2013-04-15 | 2016-02-24 | Crucell Holland B.V. | Anticorps humains se liant à la protéine g du virus respiratoire syncytial (rsv) |
KR102201554B1 (ko) | 2013-04-15 | 2021-01-12 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv g 단백질에 결합하는 인간 항체 |
PT2988780T (pt) | 2013-04-25 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Polipeptídeos f de pré-fusão do rsv solúveis estabilizados |
CN105408348B (zh) * | 2013-06-17 | 2021-07-06 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
EP3677279A1 (fr) | 2013-07-25 | 2020-07-08 | Calder Biosciences Inc. | Protéines f pré-fusion de rsv stabilisées en termes de conformation |
DK3046536T3 (en) | 2013-09-19 | 2019-03-11 | Janssen Vaccines & Prevention Bv | IMPROVED ADENOVIRUS FORMULATIONS |
US11571472B2 (en) | 2014-06-13 | 2023-02-07 | Glaxosmithkline Biologicals Sa | Immunogenic combinations |
CA2991540A1 (fr) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Polypeptides du virus respiratoire syncytial pre-fusion solubles stabilises |
ES2839880T3 (es) | 2015-07-07 | 2021-07-06 | Janssen Vaccines & Prevention Bv | Vacuna contra el VRS |
SG11201807912SA (en) | 2016-04-05 | 2018-10-30 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
EA039095B1 (ru) | 2016-04-05 | 2021-12-03 | Янссен Вэксинс Энд Превеншн Б.В. | Стабилизированные растворимые f-белки rsv до слияния |
KR102421049B1 (ko) | 2016-05-30 | 2022-07-15 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정화된 융합-전 rsv f 단백질 |
US11229692B2 (en) | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
SG11202001458SA (en) | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
MX2021005607A (es) | 2018-11-13 | 2021-06-30 | Janssen Vaccines & Prevention Bv | Proteinas f de prefusion del vrs estabilizadas. |
WO2020216844A1 (fr) | 2019-04-25 | 2020-10-29 | Janssen Vaccines & Prevention B.V. | Antigènes recombinés de la grippe |
KR20220008816A (ko) | 2019-05-15 | 2022-01-21 | 얀센 백신스 앤드 프리벤션 비.브이. | 아데노바이러스 기반 백신을 사용한 호흡기 세포융합 바이러스 감염의 예방적 치료 |
CA3177062A1 (fr) | 2020-04-02 | 2021-10-07 | Janssen Vaccines & Prevention B.V. | Compositions de vaccin stabilisees |
US20230233661A1 (en) | 2020-06-29 | 2023-07-27 | Janssen Vaccines & Prevention B.V. | Vaccine combination against repiratory syncytial virus infection |
-
2017
- 2017-04-04 SG SG11201807912SA patent/SG11201807912SA/en unknown
- 2017-04-04 US US16/091,257 patent/US10729757B2/en active Active
- 2017-04-04 JP JP2018551163A patent/JP7233928B2/ja active Active
- 2017-04-04 BR BR112018070323A patent/BR112018070323A2/pt unknown
- 2017-04-04 MA MA043762A patent/MA43762A/fr unknown
- 2017-04-04 IL IL262109A patent/IL262109B2/en unknown
- 2017-04-04 MX MX2018012095A patent/MX2018012095A/es unknown
- 2017-04-04 CN CN201780021794.1A patent/CN109069612A/zh active Pending
- 2017-04-04 MY MYPI2018703646A patent/MY193584A/en unknown
- 2017-04-04 KR KR1020187031414A patent/KR102401247B1/ko active IP Right Grant
- 2017-04-04 EA EA201892250A patent/EA201892250A1/ru unknown
- 2017-04-04 PE PE2018001916A patent/PE20190433A1/es unknown
- 2017-04-04 KR KR1020227016835A patent/KR102500970B1/ko active IP Right Grant
- 2017-04-04 WO PCT/EP2017/057957 patent/WO2017174564A1/fr active Application Filing
- 2017-04-04 KR KR1020227002657A patent/KR102491447B1/ko active IP Right Grant
- 2017-04-04 AU AU2017248018A patent/AU2017248018A1/en active Pending
- 2017-04-04 EP EP17715691.6A patent/EP3439694A1/fr active Pending
- 2017-04-04 CA CA3018139A patent/CA3018139A1/fr active Pending
-
2018
- 2018-09-07 PH PH12018501912A patent/PH12018501912A1/en unknown
- 2018-10-04 CL CL2018002825A patent/CL2018002825A1/es unknown
-
2020
- 2020-06-24 US US16/946,485 patent/US11338031B2/en active Active
-
2022
- 2022-05-20 US US17/664,290 patent/US11801297B2/en active Active
- 2022-11-24 JP JP2022187453A patent/JP2023029889A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3439694A1 (fr) | 2019-02-13 |
IL262109A (en) | 2018-11-29 |
KR102401247B1 (ko) | 2022-05-25 |
KR20180132761A (ko) | 2018-12-12 |
PH12018501912A1 (en) | 2019-06-17 |
PE20190433A1 (es) | 2019-03-21 |
SG11201807912SA (en) | 2018-10-30 |
JP2023029889A (ja) | 2023-03-07 |
IL262109B (en) | 2022-12-01 |
US20200360506A1 (en) | 2020-11-19 |
CL2018002825A1 (es) | 2018-11-16 |
MX2018012095A (es) | 2019-01-10 |
US10729757B2 (en) | 2020-08-04 |
US11801297B2 (en) | 2023-10-31 |
WO2017174564A1 (fr) | 2017-10-12 |
EA201892250A1 (ru) | 2019-03-29 |
JP7233928B2 (ja) | 2023-03-07 |
US11338031B2 (en) | 2022-05-24 |
IL262109B2 (en) | 2023-04-01 |
KR102491447B1 (ko) | 2023-01-20 |
JP2019510497A (ja) | 2019-04-18 |
KR102500970B1 (ko) | 2023-02-17 |
MY193584A (en) | 2022-10-19 |
CN109069612A (zh) | 2018-12-21 |
BR112018070323A2 (pt) | 2019-01-29 |
KR20220018618A (ko) | 2022-02-15 |
KR20220075436A (ko) | 2022-06-08 |
CA3018139A1 (fr) | 2017-10-12 |
US20220288186A1 (en) | 2022-09-15 |
US20190125854A1 (en) | 2019-05-02 |
AU2017248018A1 (en) | 2018-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43762A (fr) | Vaccin contre le rsv | |
MA46766A (fr) | Vaccin antigrippal | |
MA47787A (fr) | Vaccin contre le virus respiratoire syncytial | |
DK3393510T3 (da) | Zikavirusvaccine | |
MA46584A (fr) | Vaccin contre le cytomégalovirus humain | |
MA46317A (fr) | Vaccin contre le virus respiratoire syncytial | |
IL288541A (en) | vaccine against rsv | |
MA46316A (fr) | Vaccin contre le cytomégalovirus humain | |
GB201518684D0 (en) | Vaccine | |
DK3313436T3 (da) | Multivalent pneumokok-konjugatvaccine | |
BR112017027227A2 (pt) | Agente anti-câncer | |
MA46661A (fr) | Formulations de vaccin glycoconjugué dirigé contre expec | |
BR112017028011A2 (pt) | vacinas de gripe correspondentes antigenicamente | |
ITUB20152114A1 (it) | Dispositivo insetticida | |
DE112016003133A5 (de) | Sauggerät | |
MA44987A (fr) | Formulations de médicaments améliorées | |
DK3273821T3 (da) | Tilpasseligt smykke | |
DK3302016T3 (da) | Ophængt plov | |
GB201522132D0 (en) | Vaccine | |
DK3205661T3 (da) | Hsp70-afledt immunitetsinducerende peptid | |
FR3059559B1 (fr) | Descendeur autobloquant | |
DK3280447T3 (da) | Farmaceutiske formuleringer | |
GB201616904D0 (en) | Vaccine | |
DK3519025T3 (da) | Indgivelsesanordning | |
DK3405212T3 (da) | Cancervacciner |